Keros Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Keros Therapeutics

01/03/2024 12:00

* Keros Therapeutics Inc  KROS.OQ  reported a quarterly
adjusted
loss of $1.34​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of $-1.09.  The mean expectation of eleven analysts for the
quarter was for a loss of $1.37 per share. Wall Street expected
results to range from $-1.53 to $-1.22 per share.
    * Revenue was $143.00 thousand​; analysts expected zero. 
    * Keros Therapeutics Inc's reported EPS for the quarter was
a loss
of $1.34​.
    * The company reported a quarterly loss of $40.24 million.
    * Keros Therapeutics Inc shares had risen by 69.8% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.1%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 11 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Keros
Therapeutics Inc is $85.00 
This summary was machine generated from LSEG data March 1 at
11:59 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.37          -1.34          Beat
 Sep. 30 2023      -1.35          -1.33          Beat
 Jun. 30 2023      -1.34          -1.27          Beat
 Mar. 31 2023      -1.12          -1.26          Missed